| P2093 | author name string | Zhen Liu | |
| | Xiao-Nan Li | |
| | Baisong Zheng | |
| | Lisheng Deng | |
| | Yongcheng Song | |
| | Yuan Yao | |
| | Shuo Dong | |
| | Mari Kogiso | |
| | Hua Lv | |
| | James M Gallo | |
| | Jihui J Qiu | |
| P2860 | cites work | Cancer-associated IDH1 mutations produce 2-hydroxyglutarate | Q24320239 |
| | The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate | Q24605258 |
| | Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases | Q24632807 |
| | An integrated genomic analysis of human glioblastoma multiforme | Q24648860 |
| | IDH1 and IDH2 mutations in gliomas | Q24648948 |
| | Molecular mechanisms of "off-on switch" of activities of human IDH1 by tumor-associated mutation R132H | Q27665370 |
| | Structures of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase/Lipophilic Phosphonate Complexes | Q27667195 |
| | Antimalarial and Structural Studies of Pyridine-Containing Inhibitors of 1-Deoxyxylulose-5-phosphate Reductoisomerase | Q27678753 |
| | Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase | Q27678755 |
| | An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. | Q27852141 |
| | Function and expression of yeast mitochondrial NAD- and NADP-specific isocitrate dehydrogenases. | Q27931118 |
| | Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity | Q28116883 |
| | A cell initiating human acute myeloid leukaemia after transplantation into SCID mice | Q28131777 |
| | Cytosolic NADP(+)-dependent isocitrate dehydrogenase. Isolation of rat cDNA and study of tissue-specific and developmental expression of mRNA | Q28580849 |
| | IDH mutation impairs histone demethylation and results in a block to cell differentiation | Q29305058 |
| | Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation | Q29615366 |
| | IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype | Q29617457 |
| | Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo | Q33630257 |
| | IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study | Q33897586 |
| | A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo | Q34132933 |
| | IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours | Q34186353 |
| | Neurosphere formation is an independent predictor of clinical outcome in malignant glioma | Q35224959 |
| | Therapeutic implications of cancer stem cells. | Q35756019 |
| | Neurosphere assays: growth factors and hormone differences in tumor and nontumor studies | Q36583138 |
| | The utility and limitations of neurosphere assay, CD133 immunophenotyping and side population assay in glioma stem cell research | Q37717760 |
| | IDH mutations in glioma and acute myeloid leukemia | Q37778541 |
| | Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models | Q39294417 |
| | Mutant IDH1 is required for IDH1 mutated tumor cell growth. | Q39299157 |
| | An in vivo patient-derived model of endogenous IDH1-mutant glioma | Q39429029 |
| | The antitumor activity of the fungicide ciclopirox | Q39728484 |
| | Coordination chemistry based approach to lipophilic inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase. | Q39779186 |
| | Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy | Q41933038 |
| | Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma | Q42094345 |
| | Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations | Q42141882 |
| | Oncometabolite? IDH1 discoveries raise possibility of new metabolism targets in brain cancers and leukemia | Q43006127 |
| | Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. | Q45933613 |
| | Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. | Q45953731 |
| | Metabolism unhinged: IDH mutations in cancer. | Q55463331 |
| | Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma. | Q55466712 |
| | 2-substituted-1-naphthols as potent 5-lipoxygenase inhibitors with topical antiinflammatory activity | Q67267559 |
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 8307-8318 | |
| P577 | publication date | 2014-10-01 | |
| P1433 | published in | Journal of Medicinal Chemistry | Q900316 |
| P1476 | title | Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity | |
| P478 | volume | 57 | |